Carcinoma, Transitional Cell

"Carcinoma, Transitional Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.

Descriptor ID	D002295
MeSH Number(s)	C04.557.470.200.430
Concept/Terms	Carcinoma, Transitional Cell Carcinoma, Transitional Cell Carcinomas, Transitional Cell Cell Carcinoma, Transitional Cell Carcinomas, Transitional Transitional Cell Carcinoma Transitional Cell Carcinomas

Below are MeSH descriptors whose meaning is more general than "Carcinoma, Transitional Cell".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Neoplasms, Glandular and Epithelial [C04.557.470]
Carcinoma [C04.557.470.200]
Carcinoma, Transitional Cell [C04.557.470.200.430]

Below are MeSH descriptors whose meaning is related to "Carcinoma, Transitional Cell".

Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Transitional Cell".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Carcinoma, Transitional Cell" by people in this website by year, and whether "Carcinoma, Transitional Cell" was a major or minor topic of these publications.

Bar chart showing 29 publications over 16 distinct years, with a maximum of 5 publications in 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	1	0	1
2004	1	0	1
2005	2	0	2
2007	3	0	3
2008	2	0	2
2009	2	0	2
2011	1	0	1
2013	1	0	1
2016	1	0	1
2018	5	0	5
2019	1	0	1
2021	2	0	2
2023	1	0	1
2024	2	1	3
2025	1	0	1
2026	2	0	2

Below are the most recent publications written about "Carcinoma, Transitional Cell" by people in Profiles.

Korn P, Essien M, Pallauf M, Cheaib J, Lokeshwar S, Herrera-Caceres JO, Small A, Raskolnikov D, Kleinmann N, Shvero A, Matin SF, Labbate C, Kaimakliotis H, Tachibana I, Linehan J, Choe J, Shah O, Movassaghi M, Huang W, Persily J, Perecman A, Canes D, Pessoa RR, Potretzke A, Raman JD, Singla N. Renal function outcomes following endoscopic management of upper tract urothelial carcinoma. World J Urol. 2026 May 22; 44(1).

View in: PubMed
Korn P, Pallauf M, Herrera-Caceres JO, Lokeshwar S, Essien M, Small A, Raskolnikov D, Kleinmann N, Shvero A, Matin SF, Labbate C, Kaimakliotis H, Tachibana I, Linehan J, Choe J, Shah O, Movassaghi M, Huang W, Persily J, Perecman A, Canes D, Pessoa RR, Potretzke A, Raman JD, Singla N. Patterns of adjuvant intracavitary instillation and recurrence after endoscopic management of upper tract urothelial carcinoma. World J Urol. 2026 May 19; 44(1).

View in: PubMed
Herrera-Caceres JO, Wettstein M, Matin SF, Labbate C, Potretzke A, Rodriguez R, Singla N, Pallauf M, Huang W, Nagpal S, Kleinmann N, Shvero A, Small A, Green B, Linehan J, Choe J, Shah O, Rai A, Kaimakliotis H, Tachibana I, Canes D, Perecman A, Raman JD. Outcomes of endoscopic management for upper tract urothelial carcinoma: A multi-center international cohort analysis. Urol Oncol. 2025 Dec; 43(12):697.e1-697.e9.

View in: PubMed
Mittal K, Joshi M. Perioperative immunotherapy in urothelial carcinoma: AMBASSADOR charts the path forward. Med. 2024 12 13; 5(12):1449-1451.

View in: PubMed
Khosla H, Bhatt S, Wang MJ, Gignac G, Mittal K, Patel J. Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis. J Oncol Pharm Pract. 2024 Jul; 30(5):941-944.

View in: PubMed
Mittal K, Joshi M. FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape. Med. 2024 03 08; 5(3):176-178.

View in: PubMed
Santoni M, Myint ZW, B?ttner T, Takeshita H, Okada Y, Lam ET, Gilbert D, K?ronya Z, Tural D, Pichler R, Grande E, Crabb SJ, Kemp R, Massari F, Scagliarini S, Iacovelli R, Vau N, Basso U, Maruzzo M, Molina-Cerrillo J, Galli L, Bamias A, De Giorgi U, Zucali PA, Rizzo M, Seront E, Popovic L, Caffo O, Buti S, Kanesvaran R, Kopecky J, Kucharz J, Zeppellini A, Fiala O, Landmesser J, Ansari J, Giannatempo P, Rizzo A, Zabalza IO, Monteiro FSM, Battelli N, Calabr? F, Porta C. Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study. Cancer Immunol Immunother. 2023 Sep; 72(9):2961-2970.

View in: PubMed
Kimura Y, Fujimori M, Rajagopalan NR, Poudel K, Kim K, Nagar K, Vroomen LG, Reis H, Al-Ahmadie H, Coleman JA, Srimathveeravalli G. Macrophage activity at the site of tumor ablation can promote murine urothelial cancer via transforming growth factor-?1. Front Immunol. 2023; 14:1070196.

View in: PubMed
Rizzo A, Mollica V, Santoni M, Massari F. Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis. Clin Genitourin Cancer. 2022 10; 20(5):482-487.

View in: PubMed
Rizzo A, Mollica V, Santoni M, Ricci AD, Gadaleta-Caldarola G, Montironi R, Massari F. Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis. Future Oncol. 2022 Feb; 18(6):739-748.

View in: PubMed

People

Explore

Similar Concepts

Top Journals